16 December 2025
Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.
Earth Science Tech, Inc.
CIK: 1538495•2 Annual Reports•Latest: 2025-06-27
10-K / June 27, 2025
Revenue:$33,117,624
Income:$3,253,635
10-K / June 28, 2024
Revenue:$11,953,635
Income:$812,139
10-K / June 27, 2025
Summary of Earth Science Tech, Inc.
Business Overview
-
Type of Business: Holding company focusing on acquisitions and management of subsidiaries in healthcare, real estate, and consumer products.
-
Core Operations:
- Pharmaceutical Compounding: Operates fully licensed compounding pharmacies (RxCompound and Mister Meds) specializing in sterile and non-sterile preparations. RxCompound is licensed in numerous U.S. states and actively expanding licensure.
- Telemedicine: Platforms (Peaks and DOConsultations) facilitating asynchronous and synchronous healthcare consultations, primarily for compounded medications and wellness services, with plans to expand nationwide through healthcare provider networks.
- Healthcare Facility: Villas, a healthcare facility targeted at Spanish-speaking communities, offering sexual health treatments and physical performance solutions.
- Charitable Arm: Earth Science Foundation, Inc. (ESF), a nonprofit providing assistance for prescription costs.
- Consumer Products: MagneChef, a direct-to-consumer kitchen product brand, currently producing cooking-related products and expanding its offerings using patents and IP.
- Veterinary Market: Recently expanded into the veterinary segment through acquisition of Zoolzy.com.
-
Additional Acquisitions & Subsidiaries:
- Acquired 100% of Las Villas Health Care, Inc. and DOConsultations, LLC.
- Acquired 80% of MagneChef.
- Acquired Mister Meds operating in Abilene, Texas with advanced sterile compounding infrastructure (fully licensed in March 2025).
- Expanded into the veterinary market via Zoolzy.com.
Employees & Customers
- Employees: 76 as of March 31, 2025.
- Customers: The company has at least three significant customers who account for approximately 7%, 10%, and 9% of revenue.
- Beneficial Holders: 209 stockholders as of June 11, 2025.
Revenue & Income
- Fiscal Year Ended March 31, 2025:
- Revenue: $33,117,624
- Gross Profit: $24,300,136 (Gross margin of 73%)
- Net Income: Approximately $3,272,000
- Fiscal Year Ended March 31, 2024:
- Revenue: $11,953,635
- Gross Profit: $7,828,496 (Gross margin of 65%)
- Net Income: Approximately $812,000
Financial Highlights
- The increase in revenue from 2024 to 2025 is primarily due to higher demand for compounded medications.
- The gross margin improved, driven by better buying power and price negotiations.
- Operating expenses increased significantly, especially salaries and marketing, reflecting company growth.
- The company repurchased approximately 14.6 million shares during FY 2025 for around $1.47 million, with some shares canceled and others held in treasury.
- Cash and cash equivalents totaled approximately $1.47 million as of March 31, 2025, up from roughly $698,000 in 2024.
This summary reflects the company's scope, operational focus, recent acquisitions, financial performance, and workforce without hypothetical or external assumptions.
